Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
TFPM Triple Flag Precious Metals Corp
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
QQQ Invesco QQQ Trust
AAPL Apple Inc

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Closing Price
Day's Change
-1.72 (-0.49%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
Yesterday's News, January 26, 2023
Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity

$1.15M contribution from Lilly will fund the purchase and installation of 150 refrigeration units by Direct Relief in low- and middle-income countries around the world Eli Lilly and Company (NYSE: LLY) and Direct Relief today announced a new...(PR Newswire)

January 24, 2023
Be Nimble Foundation to Source Talent within Lilly's Skills First Program

First of its kind collaboration creates a new pathway for career opportunities to communities historically underrepresented in professional jobs Be Nimble Foundation, a 501(c)(3) social enterprise creating fully diverse and inclusive tech...(PR Newswire)

Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park

Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least...(PR Newswire)

January 20, 2023
US FDA accepts supplemental New Drug Application for Jardiance(R) for adults with chronic kidney disease

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance(R) (empagliflozin) tablets significantly reduced the risk of kidney disease progression* or cardiovascular death in...(PR Newswire)

January 19, 2023
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab

Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering Complete response letter based on limited number of patients with 12-month drug exposure data in the accelerated approval submission; no other deficiencies...(PR Newswire)

Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial...(PR Newswire)

January 04, 2023
Lilly to Participate in the J.P. Morgan Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will attendthe 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat at 6:45 p.m. Eastern time. (PR Newswire)

December 22, 2022
Lilly and ProQR to Expand RNA Editing Collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the...(PR Newswire)

December 19, 2022
December 14, 2022
Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries (PR Newswire)

December 13, 2022
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines

-- Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for...(PR Newswire)

December 12, 2022
Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock. (PR Newswire)

December 07, 2022
Phase III trial demonstrated Jardiance(R) is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

-- Jardiance(R) (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged 10-17 living with type 2 diabetes compared to...(PR Newswire)

December 06, 2022
Lilly Announces Updated Data from the Verzenio(R) (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology

The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) rates...(PR Newswire)

December 01, 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition ofAkouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class...(PR Newswire)

November 30, 2022
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease

Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm(R)(aducanumab-avwa)-treated patients at 6 months Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2%...(PR Newswire)

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

FN Media Group Presents USA News Group News Commentary USA News Group- A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this...(PR Newswire)

Lilly and Akouos Announce Expiration of Akouos Tender Offer

Eli Lilly and Company(NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the...(PR Newswire)

November 29, 2022
Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.